NEW YORK (GenomeWeb) – Interleukin Genetics reported today that its revenues for the fourth quarter of 2014 fell by more than 50 percent to $322,005 from $671,049 year over year.

The decrease was due to less deferred revenue recognized from PerioPredict test kit sales and recognized license fee income, the firm said.

Genetic testing revenues for the quarter were $298,543 compared to $424,401 in the year-ago Q4, while other revenues were $23,462 in Q4 2014 compared to $246,648 in the fourth quarter of 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.